Eric C. Holland

The paper analyzes bulk RNA-seq data from brain tumors and healthy samples to identify differential regulation of synaptic components and their impact on tumor progression and patient survival.

FFPE-CUTAC is a new assay for analyzing FFPE tissues that provides regulatory and copy-number profiles, showing robustness over time and compatibility with RNA-seq.

This paper constructs a unified transcriptional landscape of breast cancer using bulk RNA-seq data from multiple cohorts, identifying subtype and microenvironmental programs associated with therapeutic resistance.

The paper constructs a unified transcriptomic landscape of lung cancer using RNA-seq data from 1,824 tumors, identifying nine molecular clusters with distinct biological and clinical features.

This study shows that microenvironment T-type calcium channels promote glioblastoma growth by regulating neuronal and glial processes, and that blocking these channels with mibefradil enhances the effectiveness of standard therapies.

This study identifies MERTK as a therapeutic target in ZFTA-RELA-driven ependymomas through transcriptomic analysis and drug screening.

This paper develops PROTACs to degrade oncogenic TRK fusions, showing improved efficacy compared to traditional inhibitors.

The paper identifies PTEN loss as a driver of aggressive NF2 mutant meningiomas and validates a cross-species model for preclinical testing.

The paper constructs a transcriptomic landscape for medulloblastoma and ependymoma, revealing subtype-specific biology through clustering and molecular signatures.

This study investigates how C-terminal fusion partners, specifically TFE3 domains, contribute to the oncogenic activity of YAP1::TFE3 fusion proteins in tumors.

The paper identifies RNA Polymerase II hypertranscription at histone genes in cancer FFPE samples, linking it to tumor progression and aneuploidy.

This study shows ERK signaling promotes resistance to TRK inhibitors in NTRK fusion-driven glioma mouse models and suggests MEK inhibition as a potential combination therapy.

This study combines bulk RNA-Seq datasets to create a transcriptomic landscape of meningiomas, identifies subtypes with distinct biology and prognosis, and provides an interactive tool for outcome prediction.

This study shows that all-trans retinoic acid (ATRA) improves immune response in IDH-mutant gliomas by restoring the RA pathway, leading to tumor regression in mouse models and a clinical trial for human patients.

The paper shows that aggressive high-grade NF2 mutant meningiomas have reduced YAP1 activity due to increased VGLL4 and FAT3/4 expression, linked to higher recurrence risk.

The paper combines five RNA-seq datasets to create a reference landscape of human brain tissues and tumors, enabling comparative gene expression analysis across normal and neoplastic samples.

The paper identifies Ponatinib as a potent inhibitor of cytokine storm induced by SARS-CoV-2 spike protein NTD in human cells.

The paper shows that RNA-seq processing pipelines produce inconsistent abundance estimates for over 12% of genes in at least 1% of samples, raising clinical concerns.